SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001171843-22-006866
Filing Date
2022-10-28
Accepted
2022-10-28 16:05:25
Documents
12
Period of Report
2022-10-25
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Document Format Files

Seq Description Document Type Size
1 FORM 8-K f8k_102722.htm   iXBRL 8-K 25702
  Complete submission text file 0001171843-22-006866.txt   198126

Data Files

Seq Description Document Type Size
2 XBRL SCHEMA FILE crvs-20221025.xsd EX-101.SCH 3242
3 XBRL LABEL FILE crvs-20221025_lab.xml EX-101.LAB 34240
4 XBRL PRESENTATION FILE crvs-20221025_pre.xml EX-101.PRE 22369
6 EXTRACTED XBRL INSTANCE DOCUMENT f8k_102722_htm.xml XML 3610
Mailing Address 863 MITTEN ROAD SUITE 102 BURLINGAME CA 94010
Business Address 863 MITTEN ROAD SUITE 102 BURLINGAME CA 94010 (650) 900-4520
Corvus Pharmaceuticals, Inc. (Filer) CIK: 0001626971 (see all company filings)

IRS No.: 464670809 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37719 | Film No.: 221341860
SIC: 2834 Pharmaceutical Preparations